New York-based private equity group Kohlberg Kravis Roberts' (KKR) affiliate has acquired Pfizer's Capsugel business for $2.375bn, under an agreement signed between the companies.
Subscribe to our email newsletter
Capsugel is a provider of drug delivery systems for the pharmaceutical, OTC and health and nutrition industries.
Capsugel provides array of products and services, from hard gelatin, vegetarian and liquid-filled capsules, to R&D equipment and liquid formulations as part of its Licaps Drug Delivery System.
Capsugel will maintain a corporate presence in the US, with its global headquarters located in New Jersey.
Pfizer acquired Capsugel, which was created by Parke-Davis in the early 1960s, as part of its acquisition of Warner-Lambert in 2000.